logo
FDA Issues Bread Recall Update After Glass Discovered in Crusts

FDA Issues Bread Recall Update After Glass Discovered in Crusts

Newsweek3 days ago
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources.
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
The U.S. Food and Drug Administration (FDA) has ended a voluntary recall of 800 items after glass fragments were discovered in the crusts of several breads.
Maryland-based Upper Crust Bakery LP initiated the recall regarding products distributed to six states: Pennsylvania, California, Connecticut, Maryland, Delaware, and Ohio.
Upper Crust Bakery LP, operating out of Glenn Dale, voluntarily recalled three varieties of bread—Ancient Grains Hoagie Roll, Multigrain Sourdough, and Whole Grain Multigrain—after a team member discovered a glass fragment on a piece of seeded bread.
The recall initially began on April 12, 2025, and the FDA classified it as Class II on April 25, the second-highest of three risk levels, which indicates the potential for temporary or reversible health consequences.
The FDA terminated the recall on July 15.
Stock image of sourdough bread slices.
Stock image of sourdough bread slices.
Getty Images
Why it Matters
The FDA warned that consuming glass fragments could cause injuries ranging from cuts in the mouth and throat to intestinal perforation—a risk prompting significant public attention.
What To Know
According to FDA records, the recall covered three products:
Ancient Grains Hoagie Roll , 4 oz, Lot #90, 89 cases, carton code CP45, distributed frozen
, 4 oz, Lot #90, 89 cases, carton code CP45, distributed frozen Multigrain Sourdough , 18 oz, Lot #90, 699 cases, carton code CP12, distributed frozen
, 18 oz, Lot #90, 699 cases, carton code CP12, distributed frozen Whole Grain Multigrain, 20 oz, Lot #92, 30 cases, carton code CP12, distributed frozen
The bakery, operating as Crest Hill Bakery, notified the FDA after an employee discovered a glass fragment during a routine inspection. Further investigation traced the source of the glass to sunflower seeds provided by supplier Magic Flame.
Upper Crust Bakery LP stated that it immediately ceased using ingredients from the implicated supplier and removed all affected products from circulation.
"We have ceased the use of sunflower seeds from the manufacturer associated with the glass fragments, Magic Flame," the company said in a statement announcing the recall.
For consumers, the FDA and Upper Crust Bakery LP advised that bread with affected lot numbers should not be consumed but instead discarded or returned to the point of purchase for a refund. Health experts emphasized contacting a health care provider if glass ingestion is suspected due to the risk of gastrointestinal injury.
Who People Are Saying
Upper Crust Bakery LP, in a statement announcing the recall: "The recall was initiated after a vigilant team member discovered a small glass fragment on top of a piece of seeded bread."
"We remain steadfast in our commitment to upholding the highest standards of quality and safety in all our products," the company added.
The FDA warned at the time: "The agency warns that consuming glass fragments can result in significant injuries such as damage to teeth, lacerations of the mouth and throat, or perforation of the intestine."
What Happens Next
With the recall terminated as of July 15, 2025, Upper Crust Bakery LP stated that it has stopped sourcing sunflower seeds from the implicated supplier and has amended its food safety checks.
For further updates on food recalls and safety guidance, visit the FDA's official recall search portal.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Upsize LLC Opens New Male Enhancement Clinic in Dallas, Offering Revolutionary Non-Surgical Procedures
Upsize LLC Opens New Male Enhancement Clinic in Dallas, Offering Revolutionary Non-Surgical Procedures

Business Upturn

time32 minutes ago

  • Business Upturn

Upsize LLC Opens New Male Enhancement Clinic in Dallas, Offering Revolutionary Non-Surgical Procedures

DALLAS, July 24, 2025 (GLOBE NEWSWIRE) — Upsize Clinic, a leading provider of non-surgical male enhancement treatments, announces the opening of its newest clinic location in Dallas at 5232 Forest Lane, Suite 170. The clinic, led by board-certified physician Dr. Brad Sellers, offers the company's proprietary Upsize™ and Firm-X™ procedures, providing men in the Dallas-Fort Worth metroplex access to clinically proven, minimally invasive male enhancement procedures. The new Dallas location represents Upsize's continued national expansion, following the company's recent milestone of surpassing 1,500 successful procedures across its network of 20 affiliated physicians nationwide. The clinic specializes in two groundbreaking treatments: the Upsize™ procedure utilizing hyaluronic acid dermal fillers for girth enhancement, and the Firm-X™ treatment employing neuromodulator injections for improved function and appearance. 'Dallas men now have access to safe, effective enhancement options that deliver immediate results without the risks and downtime associated with surgical procedures,' said Dr. Brad Sellers, Medical Director of Upsize Dallas. 'These innovative treatments represent a significant advancement in male aesthetic medicine, offering natural-looking results that boost confidence and improve quality of life.' About Dr. Brad Sellers Dr. Sellers brings over two decades of medical expertise to his practice, having served as Medical Director and Associate Medical Director at several prominent Dallas-area Emergency Departments and Level 1 and Level 2 Trauma Centers. His extensive background in emergency medicine, combined with his Certified Physician Executive credentials from the American Association of Physician Leaders, ensures the highest standards of patient safety and care. Recently completing specialized training in male enhancement procedures through Upsize LLC, as well as neurotoxin and dermal filler certification from the National Laser Institute, Dr. Sellers has expanded his practice to focus on intimate wellness and aesthetic treatments for men. His commitment to excellence and patient-centered approach makes him uniquely qualified to deliver these innovative procedures. The Upsize™ Procedure: Non-Surgical Girth Enhancement The flagship Upsize™ procedure uses FDA-approved hyaluronic acid dermal fillers (used off-label) administered via micro-cannula to achieve natural girth enlargement and improved symmetry. Key benefits include: Immediate Results : Patients see enhancement immediately following the 30-minute in-office procedure : Patients see enhancement immediately following the 30-minute in-office procedure Minimal Downtime : Most men return to normal activities within days : Most men return to normal activities within days Reversible Option : Results can be adjusted or reversed if desired : Results can be adjusted or reversed if desired Natural Feel : Maintains natural texture and sensation : Maintains natural texture and sensation Long-Lasting: Results typically last an average of 24 months Firm-X™: Revolutionary Neuromodulator Treatment The innovative Firm-X™ treatment utilizes neurotoxin injections to enhance male sexual health and appearance. This procedure works by relaxing smooth muscles in corpus cavernosum vasculature, leading to: Enhanced blood flow and circulation Reduced retraction for a fuller appearance Improvements in erectile dysfunction The treatment involves strategic placement of 100 units of neuromodulator through four injection points, with the entire procedure completed in under 30 minutes. Meeting Growing Demand for Male Enhancement The opening of Upsize Dallas addresses increasing demand for physician administered male aesthetic treatments in North Texas. As men become more comfortable seeking enhancement options, the need for safe, effective alternatives to risky surgeries and unregulated products has grown significantly. 'Men seeking enhancement deserve access to clinically proven treatments performed by qualified medical doctors,' Dr. Sellers noted. 'Our procedures offer a discreet, professional solution that prioritizes both results and safety.' Comprehensive Patient Care The Dallas clinic provides confidential consultations where patients can discuss their options and determine the most appropriate treatment plan. Both procedures are performed in a discrete, medical-grade facility with strict adherence to safety protocols. Patients receive lifetime follow-up care at no additional charge, ensuring ongoing support and satisfaction. About Upsize LLC Headquartered in Roseville, California, Upsize LLC specializes in minimally invasive male enhancement treatments. The company's proprietary procedures have earned recognition for their safety profile, immediate results, and high patient satisfaction rates. With locations across California, Texas, Florida, New York, New Jersey, Ohio, Arizona, Nebraska, and international expansion into Panama and Canada, Upsize continues to lead innovation in male aesthetic medicine. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash

CDx Diagnostics Receives FDA Breakthrough Device Designation for Its WATS3D Test System for Esophageal Cancer
CDx Diagnostics Receives FDA Breakthrough Device Designation for Its WATS3D Test System for Esophageal Cancer

Associated Press

timean hour ago

  • Associated Press

CDx Diagnostics Receives FDA Breakthrough Device Designation for Its WATS3D Test System for Esophageal Cancer

Novel AI-powered laboratory test for diagnosis of Barrett's esophagus, with or without dysplasia SUFFERN, NEW YORK / ACCESS Newswire / July 24, 2025 / CDx Diagnostics announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation for its proprietary WATS3D diagnostic system, a 'first-of-a-kind' AI-powered digital pathology system using wide area transepithelial sampling for the diagnosis of Barrett's esophagus and early neoplastic alterations in patients at risk for disease progression. 'The Breakthrough Device Designation recognizes what the volume of clinical data has shown: the WATS3D Test improves the ability to detect dysplasia in Barrett's esophagus, offering patients and physicians an improved method of detection of patients at risk of development of esophageal cancer,' said Robert Odze, MD, a leading gastrointestinal pathologist. To meet the requirements for FDA Breakthrough Device Designation, CDx Diagnostics submitted technical and clinical evidence from large multi-center studies showing that the WATS3D Test is 'more effective' than the Seattle biopsy protocol for the diagnosis of Barrett's esophagus, dysplasia and esophageal cancer. 'With data from greater than 23,000 patients, the WATS3D Test continues to demonstrate its potential to detect early-stage neoplastic disease that might be missed with conventional biopsies,' said Karen Hoffman, MD, Director of R&D at CDx Diagnostics. 'This designation recognizes the science behind our platform and supports our ongoing efforts to improve early detection of patients at risk.' The WATS3D Test System leverages proprietary artificial intelligence (AI) enabled algorithm for analysis of high-resolution digital pathology using novel 3-dimensional images from specimens collected using the WATS3D brush to identify precancerous and cancerous cells and assess the risk of progression to cancer. The WATS3D System was developed by CDx Diagnostics and is performed in the company's CLIA-certified, CAP accredited, New York state licensed clinical laboratory in Suffern, NY. For more information, visit or contact us at [email protected]. About CDx Diagnostics CDx Diagnostics' mission is to Empower Physicians with Innovative Technology to Prevent Esophageal Cancer, One Patient at a Time. CDx Diagnostics is changing the landscape of cancer prevention and diagnosis through innovative AI-driven digital pathology solutions developed and performed in the company's CLIA-certified, CAP accredited clinical laboratory in Suffern, New York. The company's first advanced diagnostic test- the WATS3D Test system powered by the WATS3D Esophageal AI Algorithm - has FDA Breakthrough Device Designation for the diagnosis of Barrett's esophagus (BE), with and without dysplasia. About the WATS3D Test System The WATS3D Test system is an AI-powered digital pathology test system that helps prevent the progression of neoplasia via more effective identification of Barrett's esophagus (BE), low-grade dysplasia (LGD), high-grade dysplasia (HGD), and esophageal adenocarcinoma (EAC). Developed and performed by CDx Diagnostics, the WATS3D Test leverages artificial intelligence (AI) enabled analysis using the WATS3D Esophageal AI Algorithm and 3D digital imaging of samples collected using a WATS3D brush to identify precancerous and cancerous cells and evaluate the risk of progression to cancer. The WATS3D Test has been used to analyze over 400,000 patient samples to identify those requiring earlier intervention, reduce time to treatment, and improve patient outcomes. Contact Information William Standwill Marketing [email protected] 845-777-7000 SOURCE: CDx Diagnostics press release

Sutter Health names new chief operating officer
Sutter Health names new chief operating officer

Yahoo

timean hour ago

  • Yahoo

Sutter Health names new chief operating officer

This story was originally published on Healthcare Dive. To receive daily news and insights, subscribe to our free daily Healthcare Dive newsletter. Name: Kevin Manemann Previous title: Executive vice president and chief integration officer, City of Hope New title: Chief operating officer, Sutter Health Manemann, an executive with more than two decades of leadership experience in large health systems, will be Sutter Health's next chief operating officer, the Sacramento, California-based system announced Tuesday. He'll be filling a role that's sat vacant since March, when previous COO Mark Sevco left Sutter to become the CEO of Pittsburgh-based Alleghany Health Network. Manemann, who assumes his new role on Sept. 15, was formerly an executive at Southern California-based City of Hope, a $6 billion cancer care system. Prior to that, Manemann held several leadership roles at Providence St. Joseph Health, the third-largest nonprofit health system in the U.S. — including leading a $10 billion division overseeing Northern and Southern California. Manemann was at Providence for more than 16 years, according to his LinkedIn. Manemann's selection as COO is the latest in a string of executive appointments for Sutter. The system named a new chief financial officer in May, a new chief scientific officer and chief nurse officer in January, and a new senior vice president of population health in December. At Sutter, Manemann will work closely with the system's chief physician executive to co-lead clinical and nonclinical operations, according to the release. Manemann's specific purview includes Sutter's operating structure, service lines, ambulatory surgery centers, nursing and home care. One of his priorities will be to support Sutter's ambulatory growth plans, the release said. The system, already a powerhouse in Northern California with more than two dozen hospitals, has been steadily snapping up more of the region's care delivery market, adding roughly 1,000 doctors and advanced practice clinicians in 2024. Sutter also opened or expanded a number of care centers last year, while announcing other capital projects, including an advanced neurological and neurosurgical care complex and a comprehensive cancer center. The system is also pursuing growth through a joint venture with SCAN Health Plan to offer new Medicare Advantage products next year, and a deal with GE Healthcare to integrate artificial intelligence into its operations. Amid these initiatives, Sutter's finances have remained relatively stable compared to some of its nonprofit peers, according to ratings agencies. Still, the system hasn't been immune to pressures hitting hospitals, including rising costs of labor and medical supplies. Sutter reported $142 million in operating income in 2024, down from $320 million the year prior. Though, hefty investment income in both years hiked Sutter's profits to $1 billion and $1.2 billion in 2024 and 2023, respectively. Sutter is also dealing with other operational challenges facing providers, including contract spats with major insurers. Sutter also been hit with multimillion-dollar settlements this year to settle legal actions over alleged anticompetitive behavior, retirement plan mismanagement and fraudulent billing for anesthesia services. Recommended Reading Sutter Health taps new CFO

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store